Skip to content

Prognosis Stratification for pT4bN0M0 Colorectal Cancer Following Multivisceral Resection

Prognosis Stratification for pT4bN0M0 Colorectal Cancer Following Multivisceral Resection: A Multi-institutional Retrospective Analysis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06115837
Enrollment
172
Registered
2023-11-03
Start date
2023-09-01
Completion date
2023-09-26
Last updated
2023-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Colorectal Cancer, Multivisceral resection, Prognosis

Brief summary

The purpose of this study was to identify the prognostic factors of affecting pT4bN0M0 colorectal cancer patients, so as to better stratify the prognostic differences among patients with the same stage.

Detailed description

Patients with pT4b stage colorectal cancer (CRC) are a complex and special group due to the diversity of infiltrated organs, patients with the same stage often have different prognosis after multivisceral resection (MVR), some important prognostic factors have not been deeply explored, and additional prognostic factors are needed to improve the survival assessment of these patients. In this study, investigators attempted to evaluate the prognostic factors of pT4bN0M0 colorectal cancer, and then stratify the prognosis of such patients to distinguish the survival differences among different patients. This study was a multicenter retrospective cohort study based on a multicenter database which contained hospitalization.The prognostic factors of pT4bN0M0 colorectal cancer patients were analyzed, and the prognostic grading system was constructed to accurately stratify the survival of pT4bN0M0 patients.

Interventions

The prognostic factors were analyzed for pT4bN0M0 colorectal cancer after multivisceral resection

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

1. The patient was pathologically diagnosed as colorectal adenocarcinoma. 2. Patients with pT4bN0M0 colorectal cancer. 3. Patients with R0 resection.

Exclusion criteria

1. Patients with distant metastasis. 2. Patients with R1 or R2 resection. 3. Patients with lymph node metastasis 4. Recurrent colorectal cancer.

Design outcomes

Primary

MeasureTime frameDescription
Overall survivalThe endpoint of the overall survival assessment is the last follow-up or patient death. Follow-up time is up to 72 months.Overall survival is defined as the time from the surgery to death or last follow-up, regardless of disease recurrence, which was measured in months.
Cancer specific survivalThe endpoint of the cancer specific survival assessment is the patient death due to cancer. Follow-up time is up to 72 months.Cancer specific survival is defined as the time from the diagnosis to death due to cancer progression, which was measured in months.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026